Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers

Fig. 3

Impaired human epidermal growth factor receptor 2 (HER2) signaling upon endothelin A2 (Endo II) silencing in HER2-positive cancer cells. a Serum-starved HCC1954 GIPZ non-targeting (NT) and Endo II knock-down (KD)1 cells were treated with or without epidermal growth factor (EGF) (100 ng/ml) for up to 6 hours and subjected to immunoblot with antibodies to the indicated proteins. b Graphs depict the results of densitometry analysis of the EGF treatment effects on HER2 levels and phosphorylation state indicated by the ratio of phosho-specific relative to pan-reactive antibodies for the indicated proteins from three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001)

Back to article page